Michael A Skinner

US Patent:

6448023, Sep 10, 2002

Filed:

Sep 14, 2000

Appl. No.:

09/661988

Inventors:

Michael K. Skinner - Pullman WA
Jodi L. Johnson - Beaverton OR
Jeff A. Parrott - Irvine CA

Assignee:

Atairgin Technologies, Inc. - Irvine CA

International Classification:

C12Q 166

US Classification:

435 8, 435 25, 435 26, 435975, 435 4, 436 64

Abstract:

The present invention relates to non-radioactive enzymatic methods for detecting Sphingosine-1-Phosphate (S1P) in biological fluids. The present invention further relates to a method of detecting the presence of cancer in a patient by the use of these and other methods of detecting (S1P) in biological samples from a patient.

US Patent:

6716595, Apr 6, 2004

Filed:

Apr 26, 2002

Appl. No.:

10/133012

Inventors:

Michael K. Skinner - Pullman WA
Jodi L. Johnson - Beaverton WA
Jeff A. Parrott - Irvine CA

Assignee:

LPL Technologies, Inc. - Mentor OH

International Classification:

C12Q 166

US Classification:

435 8, 435 4, 435968

Abstract:

The present invention relates to non-radioactive enzymatic methods for detecting Sphingosine-1-Phosphate (S1P) in biological fluids. The present invention further relates to a method of detecting the presence of cancer in a patient by the use of these and other methods of detecting S1P in biological samples from a patient.

US Patent:

8263068, Sep 11, 2012

Filed:

Apr 29, 2005

Appl. No.:

11/587888

Inventors:

Michael K. Skinner - Pullman WA, US
Jaideep Chaudhary - Atlanta WA, US

Assignee:

Washington State University Research Foundation - Pullman WA

International Classification:

C12N 5/06
C12N 15/85
A61K 35/34
A61K 35/30
A61K 35/48
A61K 48/00
C12Q 1/68
A61P 41/00

US Classification:

424 9321, 435325, 435347, 435455, 435375, 435 6

Abstract:

The present invention relates to modified cells carrying a heterologous gene sequence encoding a protein, such as an Inhibitor of differentiation (Id) gene sequence that binds a basic helix-loop-helix (bHLH) protein to inhibit cell growth, differentiation and/or tumorigenesis of the modified cells. The modified cells are differentiated, proliferate and do not become tumorigenic when grafted into a recipient subject. Additionally, the modified cells produce a factor or factors that enhance the viability of co-grafted organs, tissues or cells. Thus, the modified cells are useful for testing agents for effects on the cells, for co-grafting with transplant organs, tissues or cells. The modified cells are also useful for enhancing the viability of thawing cells that have been cryo-preserved. In one embodiment, the modified cells are modified Sertoli cells.

US Patent:

8586307, Nov 19, 2013

Filed:

May 22, 2006

Appl. No.:

11/438752

Inventors:

Michael K. Skinner - Pullman WA, US

International Classification:

C12Q 1/68

US Classification:

435 611, 435 61

Abstract:

The present invention provides methods for detecting epigenetic, multigenerational DNA alterations caused by toxicants such as endocrine disruptor agents in a subject. The practice of the present invention can be used to diagnose and/or treat a subject having the identified DNA alterations by developing therapeutics, to prevent or delay the onset of associated diseases and/or dysfunctions.

US Patent:

20040110197, Jun 10, 2004

Filed:

Aug 26, 2003

Appl. No.:

10/647426

Inventors:

Michael Skinner - Pullman WA, US
Jodi Patton - Pullman WA, US

International Classification:

C12Q001/68

US Classification:

435/006000

Abstract:

A method of assessing tumor characteristics in tissue samples by determining the copy number or expression level of genes associated with lipid metabolism, synthesis, or action is provided. Gene copy number may be assessed directly from chromosomal material or by determining the expression level of the gene in a tissue sample. The use of physical platforms comprising immobilized nucleic acid polymers to determine copy number or expression level of lipid associated genes by hybridization techniques is also provided.

US Patent:

20070092585, Apr 26, 2007

Filed:

Oct 11, 2006

Appl. No.:

11/545909

Inventors:

MIchael Skinner - Pullman WA, US

International Classification:

A61K 31/365
A61K 31/366
A61K 31/282
A61K 31/337
A61K 33/24

US Classification:

424649000, 514454000, 514449000, 514492000, 514468000

Abstract:

The present invention provides compositions and methods for inhibiting growth of and/or killing cancer cells. The compositions include: an inhibitor of the PI3K signal transduction pathway, and additional agents, such as Triptolide.

US Patent:

20110045102, Feb 24, 2011

Filed:

Mar 22, 2010

Appl. No.:

12/661654

Inventors:

Michael K. Skinner - Pullman WA, US

International Classification:

A61K 33/24
A61K 31/5377
A61K 31/661
A61P 35/00

US Classification:

424649, 5142335, 514120

Abstract:

The present invention provides compositions and methods for inhibiting growth of and/or killing cancer cells. The compositions include: an inhibitor of the PI3K signal transduction pathway, and additional agents, such as Triptolide.

US Patent:

58213520, Oct 13, 1998

Filed:

Nov 18, 1996

Appl. No.:

8/751782

Inventors:

Nathaniel Heintz - Pelham Manor NY
John Gubbay - London, GB
Michael K. Skinner - Pullman WA

Assignee:

The Rockefeller University - New York NY

International Classification:

C07H 2104

US Classification:

536 235

Abstract:

The present invention identifies cDNA collections enriched in genes regulated in prostate homeostasis, prostate regression, and in genes regulated in programmed cell death. These novel cDNA collections provide cDNAs that encode proteins that are either unique to general programmed cell death or unique to prostate regression. These transcripts can be used as markers to monitor and/or to diagnose diseased conditions. Methods of making these collections through subtraction hybridization are described.